Eloralintide

Lilly investigational weekly amylin agonist. Lock numbers to the current trial paper before use.

What it does / how it works

Long-acting amylin-receptor agonist. Same fullness and slower-stomach logic as cagrilintide, from a different development programme. Numbers must follow the current trial paper.

Class Long-acting amylin agonist
Typical vial 5 mg
Reconstitution 1 mL BAC water per 5 mg
Storage after mix 2–8°C, use within 28 days

Protocol

Goal Dose How often How long Route
Weeks 1-4 Start well below 5 mg Once weekly 4 weeks SubQ
Weeks 5+ Step up only if tolerated Once weekly Phase 2 length SubQ

Watch: Do not copy a 5 mg week-1 start from the vial size.

Eloralintide FAQ — Australia

Eloralintide is Lilly’s long-acting amylin-receptor agonist in clinical development for obesity. It is not cagrilintide, though the receptor class overlaps.

Recommended Supplier — Eloralintide Australia

Our products offer premium-grade research materials with independent testing at a leading Australian university. Every batch is strictly verified by RP-HPLC and LC-MS. For research purposes only.

Related Research — Australia

Explore similar research-grade peptides, selected to complement your research needs.

Tesamorelin + Ipamorelin

Tesamorelin target is 1-2 mg daily. Ipamorelin target....

Super Human Blend

One serving: L-Arginine 110 mg, L-Ornithine 110 mg,....

Semax + Selank

Short course. Intranasal preferred. Then 2-4 weeks off.....

Retatrutide + Cagrilintide

5+5 mg is a late stock, not a....
Select your currency
AUD Australian dollar